drugset / Trial / NCT00462956
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the efficacy and safety of GW572016 in patients with refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2 overexpressing tumors. Patients eligible for this study must have advanced metastatic breast cancer who have previously received treatment with anthracycline and taxane.
Timeline
- Start
- 2004-06-30
- Primary completion
- 2006-12-20
- Completion
- 2006-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |